

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2022 OF THE CONDITION AND AFFAIRS OF THE

Maine Community Health Options

NAIC C	Group Code 0000 0000 NA (Current) (Prior)	IC Company Code _	15077 Employer's II	D Number 45-3416923				
Organized under the Laws of	Maine	, State o	f Domicile or Port of Er	ntry ME				
Country of Domicile		United States of Ame	erica					
Licensed as business type:		Life, Accident & He	alth					
Is HMO Federally Qualified?	es[]No[X]							
Incorporated/Organized	09/26/2011	Cor	nmenced Business	01/01/2014				
Statutory Home Office	150 Mill Street, Suite 3			Lewiston, ME, US 04240				
	(Street and Number)		(City or	Town, State, Country and Zip Code)				
Main Administrative Office		150 Mill Street, Suite (Street and Number						
	Lewiston, ME, US 04240	(Street and realing						
(City or T	own, State, Country and Zip Code)		(A	rea Code) (Telephone Number)				
Mail Address	PO Box 1121 (Street and Number or P.O. Box)			Lewiston, ME, US 04243-1121				
			Member 200	Town, State, Country and Zip Code)				
Primary Location of Books and	Records	150 Mill Street, Suit (Street and Number						
	Lewiston, ME, US 04240	, Career and Hambe						
100 000 000 000 000 000 000 000 000 000	own, State, Country and Zip Code)		(A	rea Code) (Telephone Number)				
Internet Website Address		www.healthoptions.	org					
Statutory Statement Contact	Joanne Lauterbac	h	- T.	207-330-2390				
jla	(Name) uterbach@healthoptions.org			(Area Code) (Telephone Number) 207-402-3318				
	(E-mail Address)			(FAX Number)				
		OFFICERS						
Chief Executive Officer	manufacture and the second of	Chie	Information Officer	William Kilbreth				
Chief Operating Officer	David Stuart #	Ch	ef Financial Officer	Joanne Lauterbach				
Rebecca		OTHER IRECTORS OR TRU Asher Kramer	STEES	Robert Lorenzo				
Rocell Ma		Jeff Norris Sharon Reishus		Ronnie Weston Mitchell Stein				
Holly K	orda	Judiann Ferretti Sn	nith	Paul Andrews #				
Leslie C	lark#	Jerod Cronkite #		Cory McKenna #				
State of	Maine SS Androscoggin							
all of the herein described assestatement, together with related condition and affairs of the said in accordance with the NAIC Arrules or regulations require diff respectively. Furthermore, the	its were the absolute property of the said exhibits, schedules and explanations their reporting entity as of the reporting period in unal Statement Instructions and Accountifications in reporting not related to accide to accide the score of this attestation by the described a differences due to electronic filing) of the	reporting entity, free are in contained, annexed is tated above, and of its ing Practices and Proceounting practices and pofficers also includes the	d clear from any liens ir referred to, is a full a ancome and deductions dures manual except to procedures, according a related corresponding e electronic filing may	orting entity, and that on the reporting period stated above, or claims thereon, except as herein stated, and that this nd true statement of all the assets and liabilities and of the therefrom for the period ended, and have been completed to the extent that: (1) state law may differ, or, (2) that state to the best of their information, knowledge and belief, g electronic filing with the NAIC, when required, that is an be requested by various regulators in lieu of or in addition				
Subscribed and sworn to before day of	TINE M. BROWN		Is this an original filing If no, 1. State the amendme 2. Date filed	ent number				

Notary Public, State of Maine My Commission Expires 11/3/2029

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)			123,429,471	
2.	Stocks (Schedule D):	,,			, , , , , , , , , , , , , , , , , , , ,
	2.1 Preferred stocks			0	0
	2.2 Common stocks				
3.	Mortgage loans on real estate (Schedule B):				
0.	3.1 First liens			0	0
	3.2 Other than first liens				
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$				
	encumbrances)			0	0
5.	Cash (\$4,294,131 , Schedule E - Part 1), cash equivalents				
0.	(\$				
	investments (\$, Schedule DA)	15.926.763		15.926.763	27.008.213
6.	Contract loans, (including \$ premium notes)				
7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
13.	Title plants less \$ charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	847,562		847,562	931,554
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	2,485,611	740,732	1,744,879	1,728,676
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$9,064,000) and				
	contracts subject to redetermination (\$	9,064,000		9,064,000	4,700,000
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts				
	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon				
18.2	Net deferred tax asset				
19.	Guaranty funds receivable or on deposit				
20.	Electronic data processing equipment and software	145,732	145,732	0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				
	Health care (\$4,590,180) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets	1,680,768	1,680,768	0	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	169 814 086	3 832 085	165 982 001	184 016 793
27.	From Separate Accounts, Segregated Accounts and Protected Cell		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
	Accounts			0	0
28.	Total (Lines 26 and 27)	169,814,086	3,832,085	165,982,001	184,016,793
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0		0	0
2501.	Prepaid Expenses	1,653,634	1,653,634	0	0
2502.	Miscellaneous Receivables			0	0
2503.	Security Deposits		·		0
2598.	Summary of remaining write-ins for Line 25 from overflow page	0		0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	1,680,768	1,680,768	0	0

LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, CAP	IIAL AND	Current Year		Prior Year
	<u> </u>	1	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$		Oncovered		
2.	Accrued medical incentive pool and bonus amounts				
3.	Unpaid claims adjustment expenses	,		,	/
4.	Aggregate health policy reserves, including the liability of				
	\$				
	Health Service Act	21 841 996		21 841 996	42 169 580
5.	Aggregate life policy reserves				0
6.	Property/casualty unearned premium reserves				0
7.	Aggregate health claim reserves				0
8.	Premiums received in advance				
9.	General expenses due or accrued				
	Current federal and foreign income tax payable and interest thereon				
	(including \$ on realized capital gains (losses))			0	0
10.2	Net deferred tax liability				0
11.	Ceded reinsurance premiums payable				797.962
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated	,		· ·	0
14.	Borrowed money (including \$				
	interest thereon \$ (including				
	\$	49.208		49.208	191.076
15.	Amounts due to parent, subsidiaries and affiliates				
16.	Derivatives				0
17.	Payable for securities				0
18.	Payable for securities lending				0
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$			0	0
20.	Reinsurance in unauthorized and certified (\$				
	companies			0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates				0
22.	Liability for amounts held under uninsured plans				0
23.	Aggregate write-ins for other liabilities (including \$				
	current)	150,767	0	150,767	64,053
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds				0
26.	Common capital stock				
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				
29.	Surplus notes				132,316,124
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)				
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		
	32.2 shares preferred (value included in Line 27				
	\$	xxx	xxx		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	xxx	XXX	118,783,016	120,389,917
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	165,982,001	184,016,793
	DETAILS OF WRITE-INS				
2301.	Risk Adjustment User Fee Payable	79,294		79,294	64,053
2302.	Deferred Credit	71,473		71,473	
2303.				·	
2398.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	150,767	0	150,767	64,053
2501.		XXX	XXX		0
2502.					
2503.		XXX	XXX		
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3001.					
3002.					
3003.	Summary of remaining write-ins for Line 30 from overflow page				
JU90.	Cummary or remaining write-ins for Line 30 from overflow page		XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN			District
		Curren 1	t Year 2	Prior Year 3
		Uncovered	Total	Total
1.	Member Months	xxx	349,740	284,476
			,	,
2.	Net premium income (including \$ non-health premium income)	XXX	205 096 474	164 039 529
	,		, ,	, ,
3.	Change in unearned premium reserves and reserve for rate credits			
4.	Fee-for-service (net of \$ medical expenses)	XXX	0	
5.	Risk revenue	XXX	0	
6.	Aggregate write-ins for other health care related revenues	xxx	434	215,061
7.	Aggregate write-ins for other non-health revenues			0
8.	Total revenues (Lines 2 to 7)	XXX	205,096,906	104,254,590
	Hospital and Medical:			
9.	Hospital/medical benefits			
10.	Other professional services		6,315,317	5, 152, 111
11.	Outside referrals		11,743	13,180
12.	Emergency room and out-of-area		42.982.635	35,115,697
13.	Prescription drugs			26,421,893
	·			
14.	Aggregate write-ins for other hospital and medical			
15.	Incentive pool, withhold adjustments and bonus amounts		268,553	155,000
16.	Subtotal (Lines 9 to 15)	0	212,840,955	165,983,038
	Less:			
17.	Net reinsurance recoveries		32,560,762	26,634,678
18.	Total hospital and medical (Lines 16 minus 17)			
19.	Non-health claims (net)			
20.	Claims adjustment expenses, including \$		13,432,586	11,319,822
21.	General administrative expenses		29,499,016	25,029,634
22.	Increase in reserves for life and accident and health contracts (including \$			
	increase in reserves for life only)		(13 900 000)	11 622 760
-00	Total underwriting deductions (Lines 18 through 22)			
23.				
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	(4,214,887)	(23,065,986)
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)		1,953,795	1,436,029
26.	Net realized capital gains (losses) less capital gains tax of \$		(242,749)	4,859
27.	Net investment gains (losses) (Lines 25 plus 26)	0	1,711,046	1,440,888
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered		, ,	, ,
20.	. , ,		(400 507)	(005,040)
	\$) (amount charged off \$ 186,597)]			
29.	Aggregate write-ins for other income or expenses	0	1,391,524	2,000,000
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus			
	27 plus 28 plus 29)			
31.	Federal and foreign income taxes incurred	XXX		
32.	Net income (loss) (Lines 30 minus 31)	XXX	(1,298,914)	(20,010,944)
	DETAILS OF WRITE-INS			
0601.	User Fee Revenue - Contraceptive Claims	vvv	131	215 061
	·			•
0602.				
0603				
0698.	Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	434	215,061
0701.		XXX		
0702.		XXX		
0703		XXX		
0798.	Summary of remaining write-ins for Line 7 from overflow page	xxx	0	0
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.				
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Vendor Settlement		1,391,524	2,000,000
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page		_	0
		0		
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	1,391,524	2,000,000

STATEMENT OF REVENUE AND EXPENSES (Continued)

	STATEMENT OF REVENUE AND EXPENSES	Jonanaca	/
		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	120,389,917	140,140,003
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		
26	Change in net unrealized capital gains (losses) less capital gains tax of \$		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$ Change in net unrealized foreign exchange capital gain or (loss)		
37.			
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets		
40	Change in unauthorized and certified reinsurance		
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)		(19,750,086
49.	Capital and surplus end of reporting period (Line 33 plus 48)	118,783,016	120,389,917
	DETAILS OF WRITE-INS	,	,,
4704	DETAILS OF WAITE-INS		
4701.			
4702.			
4703.		_	
4798.	Summary of remaining write-ins for Line 47 from overflow page		0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

	0/10111 2011	1	2
		· ·	_
		Current Year	Prior Year
	Cash from Operations	100 010 011	151 000 011
	Premiums collected net of reinsurance		
	Net investment income	, , ,	, ,
3.	Miscellaneous income		215,061
4.	Total (Lines 1 through 3)	196,585,095	156,567,624
5.	Benefit and loss related payments	176,320,608	163, 184, 446
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions	40,912,532	36,949,804
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)	0	0
10.	Total (Lines 5 through 9)	217,233,140	200, 134, 250
11.	Net cash from operations (Line 4 minus Line 10)	(20,648,045)	(43,566,626)
Í	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
14.	12.1 Bonds	17 1/1 000	21 020 660
		, ,	,,
	12.2 Stocks		
	12.3 Mortgage loans		0
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		0
	12.7 Miscellaneous proceeds		0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	17,141,080	21,929,660
	Cost of investments acquired (long-term only):		
	13.1 Bonds	2,014,600	94 , 174 , 446
	13.2 Stocks	0	0
	13.3 Mortgage loans	0	0
	13.4 Real estate	0	0
	13.5 Other invested assets	0	15,000
	13.6 Miscellaneous applications	0	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	2,014,600	94,189,446
14.	Net increase (decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	15,126,480	(72,259,786)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	, , , ,	, , ,
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		3,226,130
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(5,559,886)	3,092,504
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(11,081,451)	(112,733,908)
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	27,008,213	139,742,121
	19.2 End of year (Line 18 plus Line 19.1)	15,926,763	27,008,213

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

2. (Federal				
2. (Comprehensive	Medicare	Dental	Vision	Employees Health	Title XVIII	Title XIX		Other
2. (Total	(Hospital & Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
2. (Net premium income	205,096,474	205.096.474	Саррини	O,	J	Dononto i iun	ourouro	modicaid	outer riodius	
	Change in unearned premium reserves and reserve for rate credit	0									
3. F	Fee-for-service (net of \$										NO 04
	medical expenses)	0									XXX
5. <i>A</i>	Aggregate write-ins for other health care related revenues	434	0	0	0		0	0	0	434	xxx
6. <i>A</i>	Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	×××	XXX	XXX	XXX	0
7.	Total revenues (Lines 1 to 6)	205,096,908	205,096,474	0	0		0	0	0	434	0
	Hospital/medical benefits	126,414,248	126,414,248								XXX
9. (Other professional services	6,315,317	6,315,317								XXX
	Outside referrals	11,743	11,743								XXX
11. E	Emergency room and out-of-area	42,982,635	42,982,635								XXX
12. F	Prescription drugs	36,848,459	36,848,459								XXX
13. <i>A</i>	Aggregate write-ins for other hospital and medical	0	0	0	0		0	0	0	0	XXX
14. li	Incentive pool, withhold adjustments and bonus amounts .	268,553	268,553								XXX
	Subtotal (Lines 8 to 14)	212,840,955	212,840,955	0	0		0 0	0	0	0	XXX
16. N	Net reinsurance recoveries	32,560,762	32,560,762								XXX
17.	Total medical and hospital (Lines 15 minus 16)	180,280,193	180,280,193	0	0		0 0	0	0	0	XXX
18. N	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19. (Claims adjustment expenses including										
	\$8,310,944 cost containment expenses		13,432,586								
	General administrative expenses	29,499,016	29,499,016								
	Increase in reserves for accident and health contracts	(13.900.000)	(13.900.000)								XXX
	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23. T	Total underwriting deductions (Lines 17 to 22)		209,311,795	0	0	L	o l o l	0	0	0	0
	Total underwriting gain or (loss) (Line 7 minus Line 23)	(4.214.887)	(4.215.321)	0	0		0	0	0	434	0
	DETAILS OF WRITE-INS	. , , ,	, , , , ,							-	
0501. U	User Fee Revenue - Contraceptive Claims	434								434	XXX
0502.											XXX
											XXX
0598.	Summary of remaining write-ins for Line 5 from overflow	0						0	0		XXX
	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	434	n				,	0	u	434	XXX
	Totals (Lines 0501 tillu 0505 plus 0596) (Line 5 above)	404	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	^^^
0001.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0002.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow										
	page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
											XXX
											XXX
1303.											XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page	0	0				,	0	0		XXX
	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)		n	n	۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰۰		n	n	n	n .	XXX

_

ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Maine Community Health Options

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

PART 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual	136,469,914		650,000	135,819,914
Comprehensive (hospital and medical) group	69,706,686		430 , 126	69,276,560
3. Medicare Supplement				0
4. Dental only				0
5. Vision only				0
6. Federal Employees Health Benefits Plan	0			0
7. Title XVIII - Medicare	0			0
8. Title XIX - Medicaid	0			0
9. Credit A&H				0
10. Disability Income				0
11. Long-Term Care				0
12. Other health				0
13. Health subtotal (Lines 1 through 12)	206, 176,600	0	1,080,126	205,096,474
14. Life	0			0
15. Property/casualty	0			0
16. Totals (Lines 13 to 15)	206,176,600	0	1,080,126	205,096,474

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13	14
		Total	2 Individual	3 Group	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:						•								
	1.1 Direct	208,693,572	139,500,039	69, 193, 533											
	1.2 Reinsurance assumed	0													
	1.3 Reinsurance ceded	27,654,246	27,598,251	55,995											
	1.4 Net	181,039,326	111,901,788	69,137,538	0	0	0	0	0	0	0	0	0	0	0
2.	Paid medical incentive pools and														
	bonuses	531,771	351,948	179,823											
3.	Claim liability December 31, current year from Part 2A:	18,957,078	15,986,010	2,971,068	0						0	0		0	0
	3.1 Direct				0	0	0	0	0	0	0	0	0	0	0
	3.2 Reinsurance assumed	0	0 .	0	0	0	0	J0	0	ļ0	<u>0</u>	0	ļ0	0	0
	3.3 Reinsurance ceded	3,725,000	3,336,000	389,000	0	0	0]0	J0	0	0	0	0	0	0
4.	3.4 Net Claim reserve December 31, current year from Part 2D:	15,232,078	12,650,010 .	2,582,068	U	0	0	0	U	U	0	U	U	0	U
	4.1 Direct	0													
	4.2 Reinsurance assumed	0													
	4.3 Reinsurance ceded	0													
	4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Accrued medical incentive pools and bonuses, current year	325,989	220,542	105,447											
	Net health care receivables (a)	1,625,459	1,039,773	585,686											
7.	Amounts recoverable from reinsurers														
8.	December 31, current year	10,379,146	9,980,783 .	398,363											
	from Part 2A:	10 450 700	11.161.000	2.291.789	0	_			_	_					0
	8.1 Direct	13,452,789	11, 161,000	2,291,789	0	0	0	0	0	0				0	0
	8.2 Reinsurance assumed	0			0	0	0	0	0	0				0	0
	8.3 Reinsurance ceded	2,815,058	2,753,058	62,000	0	0	0	0	0	0				0	0
9.	8.4 Net	10,637,731	8,407,942 .	2,229,789	0	0	0	U	0	0	U	0	0	0	0
	9.1 Direct	0													
			-									•••••			
	9.2 Reinsurance assumed		-									•••••			
	9.3 Reinsurance ceded		0	0											
40	9.4 Net	0	0 -	0	0	0	0	J0	0	0	0	0	0	0	0
	Accrued medical incentive pools and bonuses, prior year	589,207	389,962	199,245											
	Amounts recoverable from reinsurers December 31, prior year	6,382,572	6,325,572	57,000											
12.	Incurred Benefits: 12.1 Direct	212,572,402	143,285,276	69,287,126	0	0	0	<u>0</u>	0	0	0	0	0	0	<u>0</u>
	12.2 Reinsurance assumed	0	0 .	0	0	0	0	J0	0	0	0	0	0	0	0
	12.3 Reinsurance ceded	32,560,762	31,836,404	724,358	0	0	0	0	0	0	0	0		0	0
	12.4 Net	180,011,640	111,448,872	68,562,768	0	0	0	0	0	0	0	0	0	0	0
13.	Incurred medical incentive pools and bonuses	268,553	182,528	86,025	0	0	0	0	0	0	0	0	0	0	0

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

						LIABILITYEN	D OF CORREN	IIEAN						
	1	Compre		4	5	6	7	8	9	10	11	12	13	14
		(Hospital 8	,				Fadam)							
		2	3				Federal Employees							
				Medicare			Health	Title XVIII	Title XIX		Disability	Long-Term		Other
	Total	Individual	Group	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
Reported in Process of Adjustment:														
,	5 404 000	4 004 740	4 070 004											
1.1 Direct		4,381,742	1,079,621											
1.2 Reinsurance assumed	0													
1.3 Reinsurance ceded	2,225,000	2,070,000	155,000											
1.4 Net		2,311,742	924,621	0	0	0	0	0	0	0	0	0	0	0
1.4 Net		2,311,742	924,021	0			0		U		U	0	u	u
Incurred but Unreported:														
2.1 Direct	13,495,715	11 604 268	1 891 447											
	, ,	, ,	, ,											
2.2 Reinsurance assumed														
2.3 Reinsurance ceded	1,500,000	1,266,000	234,000											
2.4 Net	11.995.715	10,338,268	1,657,447	0	0	0	0	0	0	0	0	0	0	0
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,,	-										
3. Amounts Withheld from Paid Claims														
and Capitations:														
3.1 Direct	0													
3.2 Reinsurance assumed														
3.3 Reinsurance ceded	0													
3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4 TOTALO														
4. TOTALS:														
4.1 Direct	18,957,078	15,986,010	2,971,068	0	0	0	0	0	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded		3.336.000	389.000	0		0	0	0	n	0	0	0	n	٥
		.,,	,										0	U
4.4 Net	15,232,078	12,650,010	2,582,068	0	0	0	0	0	0	0	0	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D		Claim Reserve a		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual		104,810,306	5,609	12,644,401	5,580,165	8,407,942
Comprehensive (hospital and medical) group	4,922,862	65,098,894	3,090	2,578,978	4,925,952	2,229,789
3. Medicare Supplement					0	0
4. Dental Only					0	0
5. Vision Only					0	0
6. Federal Employees Health Benefits Plan					0	0
7. Title XVIII - Medicare					0	0
8 Title XIX - Medicaid					0	0
9. Credit A&H					0	
10. Disability Income					0	
11. Long-Term Care					0	
12. Other health					0	0
13. Health subtotal (Lines 1 to 12)	10,497,418	169,909,200	8,699	15,223,379	10,506,117	10,637,731
14. Health care receivables (a)		4,989,325			0	0
15. Other non-health					0	0
16. Medical incentive pools and bonus amounts	531,771		57,436	268,553	589,207	589,207
17. Totals (Lines 13 - 14 + 15 + 16)	11,029,189	164,919,875	66,135	15,491,932	11,095,324	11,226,938

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1.	Prior	25,579	25,480	25,471	25,420	25,405	
2.	2018	241,410	273,626	273,870	276, 153	276, 150	
3.	2019	XXX	148, 191	167, 124	171,360	171,370	
4.	2020	XXX	XXX	121,984	132,708	132,447	
5.	2021	XXX	XXX	XXX	130,389	141,688	
6.	2022	XXX	XXX	XXX	XXX	164,920	

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumul	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonus Outstanding at End of Year						
Year in Which Losses Wer	lncurred 2018	2 2019	3 2020	4 2021	5 2022			
1. Prior		5,24825,4		25,420	25,405			
2. 2018		5,240 274,0	99273,870	276, 153	276, 150			
3. 2019	XXX.	170,9	954 168,214	171,360	171,370			
4. 2020	XXX.	XXX	140,352	132,776	132,447			
5. 2021	XXX	XXX	XXX	141,548	141,755			
6. 2022	XXX	XXX	XXX	XXX	180,412			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5 Claim and Claim	6	7	8	9 Total Claims and	10
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	379,263	276, 150	8,176	3.0		75.0	0			75.0
2.	2019	242,246	171,370	17,347	10.1	188,717	77.9	0 .		188,717	77.9
3.	2020	184,865	132,447	14 , 170	10.7	146,617	79.3	0		146,617	79.3
4.	2021	164,040	141,688	11,315	8.0	153,003	93.3	66	1	153,070	93.3
5.	2022	205,096	164,920	12,105	7.3	177,025	86.3	15,492	1,326	193,843	94.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

	Cumulative Net Amounts Paid						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior	25,579	25,480	25,471	25,420	25,405		
2. 2018	241,410	273,626	273,870	276 , 153	276 , 150		
3. 2019	XXX	148, 191	167, 124	171,360	171,370		
4. 2020	XXX	XXX	121,984	132,708	132,447		
5. 2021	XXX	XXX	XXX	130,389	141,688		
6. 2022	XXX	XXX	XXX	XXX	164,920		

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	Amount Paid and Claim Outs	Liability, Claim Resestanding at End of Yea	rve and Medical Incenti ar	ve Pool and Bonuses		
	1 2 3 4 5						
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior	26,248	25,480	25,471	25,420	25,405		
2. 2018	286,240	274,099	273,870	276, 153	276, 150		
3. 2019	XXX	170,954	168,214	171,360	171,370		
4. 2020	XXX	XXX	140,352	132,776	132,447		
5. 2021	XXX	XXX	XXX	141,548	141,755		
6. 2022	XXX	XXX	XXX	XXX	180,412		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	379,263	276, 150	8,176	3.0		75.0	0	0	284,326	75.0
2.	2019	242,246	171,370	17,347	10.1	188,717	77.9	0	0	188,717	77.9
3.	2020	184,865	132,447	14,170	10.7	146,617	79.3	0	0	146,617	79.3
4.	2021	164,040	141,688	11,315	8.0	153,003	93.3	66	1	153,070	93.3
5.	2022	205,096	164,920	12,105	7.3	177,025	86.3	15,492	1,326	193,843	94.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY														
		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13
		Total	2 Individual	3 Group	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves	0												
2.	Additional policy reserves (a)	15,800,000	15,800,000											
3.	Reserve for future contingent benefits	0												
4.	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)	1,434,756	1,434,756											
5.	Aggregate write-ins for other policy reserves	4,607,240	4,607,240	0	0	0	0	0	0	0	0	0	0	0
6.	Totals (gross)	21,841,996	21,841,996	0	0	0	0	0	0	0	0			0
7.	Reinsurance ceded	0												
8.	Totals (Net)(Page 3, Line 4)	21,841,996	21,841,996	0	0	0	0	0	0	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0												
10.	Reserve for future contingent benefits	0												
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0												
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.	Risk Adjustment Payable	3,885,000	3,885,000											
0502.	High-Cost Risk Pool Payable	722,240	722,240											
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	4,607,240	4,607,240	0	0	0	0	0	0	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$15,800,000 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			YSIS OF EXPENSE			
		Claim Adjustme 1 Cost Containment	2 Other Claim Adjustment	3 General Administrative	4 Investment	5
	5.1.6	Expenses	Expenses	Expenses	Expenses	Total
1.	Rent (\$ for occupancy of			226 667		200 667
	own building)					226,667
2.	-	4,637,100	1,524,950	10,986,553		17,348,009
3.	Commissions (less \$			0.040.000		0.040.000
	ceded plus \$ assumed) .					
4.	Legal fees and expenses					
5.	Certifications and accreditation fees					·
6.	Auditing, actuarial and other consulting services			1,367,541		
7.	Traveling expenses			46,703		
8.	Marketing and advertising					
9.	Postage, express and telephone					
10.	Printing and office supplies			202,770		·
11.	Occupancy, depreciation and amortization			ŕ		254,060
12.	Equipment			25 , 143		25,143
13.	Cost or depreciation of EDP equipment and software			82,814		82,814
14.	Outsourced services including EDP, claims, and other services	3,116,698	3,596,691	3,570,910	262,313	10,546,612
15.	Boards, bureaus and association fees			157,446		157,446
16.	Insurance, except on real estate			480,377		480,377
17.	Collection and bank service charges			547,011		547,011
18.	Group service and administration fees					0
19.	Reimbursements by uninsured plans					0
20.	Reimbursements from fiscal intermediaries					0
21.	Real estate expenses			136,385		136,385
22.	Real estate taxes					0
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes			200		200
	23.2 State premium taxes			200		200
	23.3 Regulatory authority licenses and fees			4,916,569		4,916,569
	23.4 Payroll taxes			1,067,505		1,067,505
	23.5 Other (excluding federal income and real estate taxes)			503,594		503,594
24.	Investment expenses not included elsewhere					0
25.	Aggregate write-ins for expenses	0	0	35,014	0	35,014
26.	Total expenses incurred (Lines 1 to 25)	8 310 945	5 121 641		262 313	
27.				4,137,690		5,464,685
28.	, , , , , , , , , , , , , , , , , , ,		, ,	3,446,534		
29.	Amounts receivable relating to uninsured plans,					
30.	Amounts receivable relating to uninsured plans,					0
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	8,310,945	4,736,341	28,807,860	262,313	42,117,459
	DETAILS OF WRITE-INS	5,515,610	1,700,011	20,007,000	202,010	12,111,400
2501	Fines and Penalties Expense			35 014		35,014
2501.	·					,
2502. 2503.						
	Summary of remaining write-ins for Line 25 from		0	^		_
2599.	overflow page			0	0	0
(a) India	above) des management fees of \$ to	0 o affiliates and \$	0	35,014 n-affiliates.	0	35,014

(a) Includes management fees of \$ to affiliates and \$ to non-affiliates

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds	(a)31,000	31,000
1.1	Bonds exempt from U.S. tax	(a)	
1.2	Other bonds (unaffiliated)	(a)2, 139,600	1,995,504
1.3	Bonds of affiliates	(a)0	J0
2.1	Preferred stocks (unaffiliated)	(b)0	J0
2.11	Preferred stocks of affiliates		
2.2	Common stocks (unaffiliated)	0	J0
2.21	Common stocks of affiliates		0
3.	Mortgage loans		ı0
4.	Real estate	* *	0
5	Contract Loans	\ <i>\</i>	ı0
6	Cash, cash equivalents and short-term investments		
7	Derivative instruments	` '	· · · · · · · · · · · · · · · · · · ·
8.	Other invested assets	` '	0
9.	Aggregate write-ins for investment income		0
10.	Total gross investment income	0 040 500	2.223.872
11.	Investment expenses		(g)262,313
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		. ,
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		1.953.795
1	DETAILS OF WRITE-INS		.,,,,,,,,
0901.			1
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page		0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0
1501.	Totals (Ellies 500 Fitting 500 pius 5000) (Ellie 0, abovo)	•	· ·
1501.			
1502.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0
1399.	Totals (Lines 1501 tillu 1505 plus 1596) (Line 15, above)		
(a) Inclu	ides \$	00 paid for accrued interpretation	erest on purchases.
(b) Inclu	ides \$ 0 accrual of discount less \$ 0 amortization of premium and less \$. 0 paid for accrued div	ridends on purchases.
(c) Inclu	des \$ 0 accrual of discount less \$ 0 amortization of premium and less \$. 0 paid for accrued into	erest on purchases.
	ides \$ 0 for company's occupancy of its own buildings; and excludes \$		•
	ides \$ 0 accrual of discount less \$ 0 amortization of premium and less \$		erest on purchases
	des\$0 accrual of discount less\$	- paid for doorded file	s. set on paronasco.
(I) IIICIU	ues v accidat di discount less v annonzation di premium.		

EXHIBIT OF CAPITAL GAINS (LOSSES)

segregated and Separate Accounts.

			•		- /	
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	0	0	0	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	(242,749)	0	(242,749)	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates			0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.		0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	0	0	0	0	0
7.	Derivative instruments	0	0	0	0	0
8.		0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	(242,749)	0	(242,749)	0	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,	0			0	
0000.	above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	1 A33L13	2	3
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)			0
	Stocks (Schedule D):			
	2.1 Preferred stocks			0
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
0.	3.1 First liens			0
	3.2 Other than first liens			
4.	Real estate (Schedule A):			
٦.	4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments			
J.	(Schedule DA)			0
6.	Contract loans			0
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)	221,500	221,500	0
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
10.	15.1 Uncollected premiums and agents' balances in the course of collection	740 732	820 117	79 385
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
10.				0
	16.1 Amounts recoverable from reinsurers			
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon			
	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets	1,680,768	1,546,631	(134,137)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	3,832,085	3,524,098	(307,987)
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0
28.	Total (Lines 26 and 27)	3,832,085	3,524,098	(307,987)
1101.	DETAILS OF WRITE-INS			
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page			
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Expense			
2501.	Miscellaneous Receivables	, ,	, ,	` ' '
2502. 2503.	Security Deposits			
	Summary of remaining write-ins for Line 25 from overflow page	-	*	
2598.			1 546 621	
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	1,680,768	1,546,631	(134, 137)

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

			Total Members at End of			6
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
Health Maintenance Organizations		7,356	7,191	7,298	7,178	86,656
Provider Service Organizations						
Preferred Provider Organizations		21,833	21,789	22,127	22 , 122	263,084
4. Point of Service						
5. Indemnity Only						
Aggregate write-ins for other lines of business	0	0	0	0	0	0
7. Total	22,984	29,189	28,980	29,425	29,300	349,740
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Maine Community Health Options (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Maine Bureau of Insurance (the "Bureau").

A reconciliation of the Company's net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the Bureau is shown below:

		SSAP#	F/S Page	F/S Line #	2022	2021
<u>NET</u> <u>INCOME</u>						
(1)	Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (1,298,914)	\$(20,010,944)
(2)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP					_
(3)	State Permitted Practices that are an increase/(decrease) from NAIC SAP				_	
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ (1,298,914)	\$(20,010,944)
<u>SURPLUS</u>						
(5)	Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$118,783,016	\$120,389,917
(6)	State Prescribed Practices that are increase/(decrease) from NAIC SAP					
(7)	State Permitted Practices that are an increase/(decrease) from NAIC SAP					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$118,783,016	\$120,389,917

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC Annual Statement Instructions and NAIC SAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policy

Health premiums are earned over the term of the related insurance policies and reinsurance contracts. Premiums written are reported net of reinsurance ceded and experience rating refunds. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates are subject to approval by the Bureau. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year at the date of acquisition and are reported at amortized cost, which approximates fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the scientific interest method, using yield to maturity.
- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans on real estate.
- (6) Loan-backed securities are stated at either amortized cost or the lower of amortized cost or fair value. The retrospective adjustment method is used to value all securities.
- (7) The Company owns 100% of Community Options LLC.
- (8) The Company has an investment in an unaffiliated limited liability company. The Company reports this investment as an other long-term invested asset on Schedule BA. The asset, which is carried at its Generally Accepted Accounting Principles equity, is nonadmitted for statutory reporting purposes.
- (9) The Company has no derivative instruments.

- (10) The Company uses anticipated investment income as a factor in the premium deficiency reserve calculation.
- (11) Unpaid claims and claims adjustment expenses included management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considered health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claims adjustment expenses are based on assumptions and estimates. While management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continuously reviewed and changes in estimates are incorporated into current period estimates.
- (12) The Company has not modified its capitalization policy from the prior period.
- (13) Pharmaceutical rebate receivables are recorded when earned based on actual rebate receivables billed and an estimate of receivables based on current utilization of specific pharmaceuticals and provider contract terms.

D. Going Concern

Not applicable

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable.

2. Accounting Changes and Corrections of Errors

A. Accounting Changes

As of December 31, 2022, The Company changed the reporting of the receivable and payable for the high-cost risk pool (HCRP) under the Affordable Care Act's (ACA) risk adjustment program. The HCRP receivable is now reported on page 2, line 15.3, and the HCRP payable is now reported on page 3, line 4. There were no other accounting changes during the years ended December 31, 2022 and 2021.

B. Corrections of Errors

There were no corrections of errors during the years ended December 31, 2022 and 2021.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2022 and 2021.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2022 or 2021.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2022 or 2021.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2022 or 2021.

D. Loan-Backed Securities

- (1) Prepayment assumptions for mortgage-backed securities were obtained from broker-dealer survey values. The Company used various third-party pricing party sources in determining the market value of its loan-backed securities.
- (2) The Company did not recognize other-than-temporary impairments on its loan-backed securities during the years ended December 31, 2022 and 2021.
- (3) The Company did not recognize other-than-temporary impairments on its loan-backed securities during the years ended December 31, 2022 and 2021.
- (4) The Company did not recognize other-than-temporary impairments on its loan-backed securities at December 31, 2022 and 2021.
- (5) The Company had no impaired loan-backed securities for which an other-than-temporary impairment had not been recognized in earnings at December 31, 2022 and 2021.
- (6) The Company had no impaired loan-backed securities at December 31, 2022 and 2021.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

The Company entered into a repurchase investment sweep arrangement whereby the banking institution automatically sweeps excess available account funds into overnight repurchase agreements based on predefined increments. On the next banking day, the funds are returned to the Company's bank accounts. These funds are secured by an obligation of the United States of America. This arrangement was terminated during 2022. The Company did not enter securities lending transactions during 2022 or 2021.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as a secured borrowing at December 31, 2022 or 2021.

G. Reverse Repurchase Agreements Transaction Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2022 or 2021.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreements transactions accounted for as a sale at December 31, 2022 or 2021.

I. Reverse Repurchase Agreements Transactions Accounted for a Sale

The Company did not enter into reverse repurchase agreements transactions accounted for as a sale at December 31, 2022 or 2021.

J. Real Estate

The Company did not have investments in real estate at December 31, 2022 and 2021.

K. Low-Income Housing Tax Credits (LIHTC)

The Company did not invest in properties generating low-income housing tax credits during 2022 or 2021.

L. Restricted Assets

(1) Restricted Assets (Including Pledged)

	Т .		_				_
	1	2	3	4	5	6	7
	Total Gross				Total	Gross	
	(Admitted &	Total Gross		Total	Total Current	(Admitted &	
	Nonadmitted)			Current		Nonadmitted &	Admitted
	Restricted	Nonadmitted)	Increase/	Year	Admitted	Restricted to	Restricted to
Restricted Asset Category		Restricted from	(Decrease)	Admitted		Total Assets	Total Admitted
Restricted Asset Category	Year	Prior Year	(1 minus 2)		(1 minus 4)	(a)	Assets (b)
a. Subject to contractual	rear	Thorrea	(111111032)	Restricted	(11111103 4)	(α)	7133613 (8)
a. Subject to contractual obligation for which							
liability is not shown	¢	\$	\$	¢	\$		
b. Collateral held under	٠	γ		٠	٠	•••••	
security lending agreements							
c. Subject to repurchase							
agreements							
d. Subject to reverse							
repurchase agreements							
e. Subject to dollar							
repurchase agreements							
f. Subject to dollar reverse							
repurchase agreements							
g. Placed under option							
contracts							
h. Letter stock or securities							
restricted as to sale -							
excluding FHLB capital							
stock							
i. FHLB capital stock							
j. On deposit with states	110,916	110,107	809		110,916	0.065	0.067
k. On deposit with other							
regulatory bodies							
I. Pledged collateral to FHLB							
(including assets backing							
funding agreements)							
m. Pledged as collateral not							
captured in other							
categories							
n. Other restricted assets							
			\$ 209	\$			0.067
o. Total Restricted Assets	\$110,916	\$110,107	\$809	\$	\$ 110,916	0.065	0.067

- (a) Column 1 divided by Asset Page, Column 1, Line 28
- (b) Column 5 divided by Asset Page, Column 3, Line 28
- (2) Detail of Assets Pledged as Collateral Not Captured in Other Categories Not applicable.
- (3) Detail of Other Restricted Assets Not applicable.
- (4) Collateral Received and Reflected as Assets within the Reporting Entity's Financial Statements Not applicable.

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2022 and 2021.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting and netting of assets and liabilities at December 31, 2022 and 2021.

O. 5GI Securities

The Company did not have any 5GI securities at December 31, 2022 and 2021.

P. Short Sales

The Company did not have any short sales at December 31, 2022 and 2021.

Q. Prepayment Penalty and Acceleration Fees

The Company did not have any prepayment penalty or acceleration fees at December 31, 2022 and 2021.

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in any cash pools at December 31, 2022 and 2021.

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company had no investments in joint ventures, partnerships or limited liability companies that exceeded 10% of its admitted assets at December 31, 2022 or 2021.
- **B.** Not applicable.

7. Investment Income

- A. All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- B. At December 31, 2022 and 2021 there was no non-admitted accrued investment income.

8. Derivative Instruments

The Company had no derivative instruments at December 31, 2022 or 2021.

9. Income Taxes

The Company is exempt from Federal income taxes under Section 501(c)(29) of the Internal Revenue Code. Accordingly, no provision for income taxes has been made in the accompanying financial statements. The Company's federal income tax return is not consolidated with any other entity.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

- A. Nature of the Relationship: The Company owns 100% of Community Options, LLC.
- B. Significant Transactions for Each Period: Not applicable.
- C. Transactions with Related Parties not Reported on Schedule Y: Not applicable.
- D. Amounts Due from or to Related Parties: Not applicable.
- E. Management and Service Contracts and Cost Sharing Arrangements: Not applicable.
- F. Guarantees or Undertakings: Not applicable.
- G. Nature of Control Relationships that Could Affect Operations or Financial Position: Not applicable.
- H. Amount Deducted for Investment to Upstream Company: Not applicable.

- I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets: Not applicable.
- J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated Companies ("SCA"): Not applicable.
- K. Investment in a Foreign Insurance Subsidiary: Not applicable.
- L. Investments in Downstream Non-Insurance Holding Companies: Not applicable.
- M. All SCA investments: Not applicable.
- N. Investment in Insurance SCAs: Not applicable.
- O. SCA and SSAP No. 48 Entity Loss Tracking: Not applicable.

11. Debt

A. Debt, including Capital Notes

At December 31, 2022 and 2021 the Company had outstanding a note payable, with a face value and a carry value of \$28,072 and \$109,007, respectively, to Mill 3 Storehouse, LLC, for expenses related to leasehold improvements. The note payable was issued May 1, 2014 (the commencement date) and is payable in monthly principal and interest payments of \$7,106 until April 2023. The note is contingent upon the Company remaining in the leased space. If the Company does not renew the lease after the initial five year term, the note will become due 60 days after cancellation. The note carries interest at 6%. During 2022 and 2021, the Company paid interest of \$4,339 and \$9,041 on this note. This note is off-set against leasehold improvements in line 21 of the Asset Schedule. The Mill 3 Storehouse, LLC lease is ending on April 30, 2023, and the Company is currently negotiating a lease at a new facility.

At December 31, 2022 and 2021 the Company had outstanding a note payable, with a face value and a carry value of \$21,136 and \$82,070, respectively, to Mill 2 Storehouse, LLC, for expenses related to leasehold improvements. The note payable was issued October 1, 2014 (the commencement date) and is payable in monthly principal and interest payments of \$5,350 until April 2023. The note is contingent upon the Company remaining in the leased space. If the Company does not renew the lease after the initial five year term, the note will become due 60 days after cancellation. The note carries interest at 6%. During 2022 and 2021, the Company paid interest of \$3,267 and \$6,807 on this note. The Mill 2 Storehouse, LLC lease is ending on April 30, 2023, and the Company is currently negotiating a lease at a new facility.

Debt maturities subsequent to December 31, 2022 consist of:

2023	\$	49,208
2024		-
2025 or after	_	_
Total	Ś	49.208

The Company does not have any reverse repurchase agreements at December 31, 2022 or 2021.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB Agreements outstanding at December 31, 2022 or 2021.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable.

B. Defined Benefit Plan Investment Policies and Strategies

Not applicable.

C. Defined Benefit Plan Fair Value of Assets

Not applicable.

D. Defined Benefit Plan Basis Used to Determine the Overall Expected Rate of Return on Assets Assumption

Not applicable.

E. Defined Contribution Plan

The Company maintains a Section 401(k) Retirement Plan for its employees. For the years ended December 31, 2022 and 2021, elective employee deferrals were matched by the Company in an amount equal to 100% of such deferrals up to a maximum match of 3% of compensation plus 50% of such elective deferrals equal to more than 3% but not exceeding 5% of compensation. The Company's contribution to the plan was \$363,767 and \$416,758 for 2022 and 2021, respectively.

The Company owns a Section 457(b) Plan (the "Plan") for its employees. The Plan limits participation to a select group of management or highly compensated employees (or "top hat" group) and is exempt from most Employee Retirement Income Security Act of 1974 requirements. The value of the Plan funds was \$144,000 and \$144,000 at December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021 the fair market value of the funds is \$217,701 and \$247,780, respectively.

F. Multiemployer Plans

Not applicable.

G. Consolidated/Holding Company Plans

Not applicable.

H. Postemployment Benefits and Compensated Absences

Liabilities for earned not yet taken vacation benefits have been accrued as of December 31, 2022 and 2021.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- **A.** Outstanding Shares: The Company has no outstanding shares.
- B. Preferred Stock: The Company has no preferred stock outstanding.
- **C. Dividend Restrictions:** Not applicable.
- **D. Dividends Paid:** Not applicable.

- **E.** Maximum Ordinary Dividend during 2022: Not applicable.
- **F. Unassigned Surplus Restrictions:** There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- **G.** Mutual Surplus Advances: Not applicable.
- H. Company Stock Held for Special Purpose: Not applicable.
- I. Changes in Special Surplus Funds: Not applicable.
- J. Changes in Unassigned Funds: Not applicable.
- **K. Surplus Notes:** The Company issued the following surplus debentures or similar obligations:

1	2	3	4	5	6	7	8
				Is Surplus		Carrying	Unapproved
				Note Holder	Carrying Value	Value of	Interest
Item		Interest	Original Issue	a Related	of	Note Current	And/Or
Number	Date Issued	Rate	Amount of Note	Party (Y/N)	Note Prior Year	Year *	Principal
1001	03/29/2012	0.000%	\$ 12,506,124	N	\$ 12,506,124	\$ 12,506,124	\$ -
1002	02/22/2013	0.370%	\$119,810,000	N	\$119,810,000	\$119,810,000	\$ 2,944,940
Total	XXX	XXXX	\$132,316,124	XXX	\$132,316,124	\$132,316,124	\$ 2,944,940

^{*} Total should agree with Page 3, Line 29.

1	9	10	11	12	13	14
			Current Year			
			Interest Offset			
			Percentage (not			
	Current Year	Life-To-Date	including amounts			
Item	Interest Expense	Interest Expense	paid to a 3rd party	Current Year	Life-To-Date	
Number	Recognized	Recognized	liquidity provider).	Principal Paid	Principal Paid	Date of Maturity
1001	\$ -	\$ -	-	\$ -	\$ -	08/12/2020
1002	\$ -	\$ -	-	\$ -	\$ -	12/30/2030
Total	\$ -	\$ -	XXX	\$ -	\$ -	XXX

1	15	16	17	18	19
			Were Surplus		
		Surplus Note	Note proceeds		
		payments	used to		
		subject to	purchase an		
	Are Surplus	administrative	asset directly		
	Note payments	offsetting	from the holder	Is Asset Issuer	Type of Assets
Item	contractually	provisions?	of the surplus	a Related	Received Upon
Number	linked? (Y/N)	(Y/N)	note? (Y/N)	Party (Y/N)	Issuance
1001	Υ	N	N	N	Cash
1002	Υ	N	N	N	Cash
Total	XXX	XXX	XXX	XXX	XXX

1	20	21	22
			Is Liquidity Source
	Principal Amount of		a Related Party to
ltem	Assets Received	Book/Adjusted Carry	the Surplus Note
Number	Upon Issuance	Value of Assets	Issuer? (Y/N)
1001	\$ 12,506,124	\$ 12,506,124	N
1002	\$119,810,000	\$119,810,000	N
Total	\$132,316,124	\$132,316,124	XXX

At December 31, 2022 and 2021, the surplus notes had carrying values of \$119,810,000 and \$12,506,124. Under the terms of the \$119,800,000 surplus notes, each individual draw is repayable fifteen years from the date of the draw, with the last repayment due December 30, 2030. Under the terms of the \$12,506,124 surplus notes, each individual draw is repayable five years from the date of the draw, with the last repayment due August 12, 2020. Accrued interest payments are due annually beginning in 2020 for draws made prior to 2019. Interest rates for the surplus notes of \$119,810,000 and \$12,506,124 are accrued at 0.37% and 0.00%, respectively.

The surplus note has the following repayment conditions and restrictions: Each payment of interest on and principal of the surplus note may be made only with the prior approval of the Commissioner of Insurance of the State of Maine and only to the extent the Company has sufficient surplus earnings to make such payment. During 2022 and 2021, the Company made no interest or principal payments and, because interest payments have not been approved by the Commissioner of Insurance, accrued interest on the surplus note is excluded from these financial statements.

The surplus note has the following subordination terms: Because the intent of the note is to provide financing that meets the definition of "risk based capital" for State Insurance Laws purposes, the note will have a claim on cash flow and reserves of the Company that is subordinate to (a) claims payments, (b) basic operating expenses, and (c) maintenance of required reserve funds while the Company is operating as a CO-OP under State Insurance Laws.

- L. Restatement Due to Prior Quasi-Reorganizations: The Company had no restatements due to prior quasi-reorganizations.
- **M. Quasi-Reorganizations over Prior 10 Years:** The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company has no contingent commitments at December 31, 2022 and 2021.

B. Assessments

The Company has identified no assessments that could have a material financial effect on these statements at December 31, 2022 and 2021.

C. Gain Contingencies

In January 2022, the Company and the United States Government entered into a joint stipulation agreement wherein the parties agreed that the Company was entitled to payment under section 1402 of the Affordable Care Act for unpaid Cost Share Reduction payments through December 31, 2017. In addition, the Company entered into an agreement with a supplier settling an outstanding dispute. Payment for both these matters was received during the first quarter of 2022. There were no additional significant changes during 2022.

D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

At December 31, 2022 and 2021, the Company reported admitted assets of \$832,022 and \$706,852, respectively, in premiums receivable due from policyholders. Based upon Company experience, any uncollectible receivables are not expected to exceed \$226,415 that was nonadmitted at December 31, 2022; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Leases

(1) The Company leases office space under various non-cancelable operating leases. Related lease expense for 2022 and 2021 was \$226,667 and \$216,667, respectively.

Certain rental commitments have renewal options extending until April 2023 and include incremental increases in the per-foot cost each year. Certain rental commitments include favorable purchase options at the end of the lease term. However, the current facility lease is ending on April 30, 2023, and CHO is currently negotiating a lease at a new facility.

(2) At December 31, 2022, the minimum aggregate rental commitments are as follows:

Operating
<u>Leases</u>
76,666
\$ 76,666

(3) The Company is not involved in any sales-leaseback transactions.

B. Lessor Leases

- (1) The Company has not entered into any operating leases.
- (2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company had no financial instruments with off-balance sheet risk at December 31, 2022 and 2021.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2022, there were no significant concentrations

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2022 and 2021.

B. Transfer and Servicing of Financial Assets

Not applicable at December 31, 2022 or 2021.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance yield on the investments.
- (2) At December 31, 2022 and 2021, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured

- A. Administrative Services Only Plans: Not applicable.
- B. Administrative Services Contract Plans: Not applicable.
- C. Medicare or Similarly Structured Cost-Based Reimbursement Contract: Not applicable.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company had no premiums written by managing general agents or third-party administrators during the years ended December 31, 2022 and 2021.

20. Fair Value Measurements

A. Fair Value Measurements

The Company had no material assets or liabilities measured and reported at fair value at December 31, 2022.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable.

C. Financial Instruments

Certain of the Company's financial instruments are measured at fair value. The fair values of these instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by GAAP. The following are the levels of the hierarchy and a brief description of the type of valuation information (inputs) that qualifies a financial asset or liability for each level:

- Level 1 Unadjusted quoted prices for identical assets or liabilities in active markets.
- Level 2 Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
- Level 3 Developed from unobservable data, reflecting the Organization's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classify these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

There have been no significant changes in the valuation techniques during 2022.

The carrying values and estimated fair values of the Company's financial instruments at December 31, 2022 were as follows:

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	Net Asset Value (NAV)	Not Practicable (Carrying Value)	
Bonds	\$110,235,375	\$123,429,471	\$	\$123,429,471	\$	\$	\$
Cash Equivalents	\$11,632,632	\$11,632,632	\$11,632,632	\$	\$	\$	\$

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value at December 31, 2022 and 2021.

E. Investments Measured at Net Asset Value (NAV) Practical Expedient

The Company had no investments measured using the NAV practical expedient at December 31, 2022 and 2021.

21. Other Items

- A. Unusual or Infrequent Items: Not applicable.
- B. Troubled Debt Restructuring: Debtors: Not applicable.
- C. Other Disclosures:

Bonds with an amortized cost of \$110,916 and \$110,107, respectively, were on deposit with a regulatory authority at December 31, 2022 and 2021.

- D. Business Interruption Insurance Recoveries: Not applicable.
- E. State Transferable and Non-transferable Tax Credits: Not applicable.
- F. Subprime-Mortgage-Related Risk Exposure: Not applicable.
- G. Retained Assets: Not Applicable.
- H. Insurance-Linked Securities (ILS) Contracts: Not applicable.
- I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy: Not Applicable

22. Events Subsequent

Subsequent events have been considered through February 27, 2023 for the statutory statements issued on February 28, 2023. There were no events occurring subsequent to December 31, 2022 requiring disclosure.

23. Reinsurance

A. Ceded Reinsurance Report.

Section 1 – General Interrogatories

1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly by the Company or by any representative, officer, trustee or director of the Company?

Yes () No (X)

2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, beneficiary, a creditor or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 – Ceded Reinsurance Report – Part A

1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

Yes () No (X)

2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsurance policies?

Yes () No (X)

Section 3 - Ceded Reinsurance Report - Part B

- What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate. Not applicable
- 2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance as of December 31, 2022 and 2021.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during the years ended December 31, 2022 and 2021.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not applicable at December 31, 2022 and 2021.

E. Reinsurance Credit

Not applicable at December 31, 2022 and 2021.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

- **A.** The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.
- **B.** The Company records retrospective premium as an adjustment to earned premium.
- **C.** The amount of premiums written by the Company at December 31, 2022 that was subject to retrospective rating features was \$206,176,600 which represented 100% of the total net premiums written.

D. Medical loss ratio rebates required pursuant to the Public Health Service Act.

	1	T		1	
	1	2	3	4	5
	Individual	Small Group Employer	Large Group Employer	Other Categorie s with Rebates	Total
Prior Reporting Year					
(1) Medical loss ratio rebates incurred	\$ 11,151,383	-	\$ (170,013)	-	\$ 10,981,370
(2) Medical loss ratio rebates paid	\$ 13,538,989	-	\$ 286,430	-	\$ 13,825,419
(3) Medical loss ratio rebates unpaid	\$ 6,569,580	-	-	-	\$ 6,569,580
(4) Plus reinsurance assumed amounts	XXXX	XXXX	XXXX	XXXX	XXXX
(5) Less reinsurance ceded amounts	XXXX	XXXX	XXXX	xxxx	XXXX
(6) Rebates unpaid net of reinsurance	XXXX	XXXX	XXXX	XXXX	XXXX
Current Reporting Year- to-Date					
(1) Medical loss ratio rebates incurred	\$ 2,930,080	-	-	-	\$ 2,930,080
(2) Medical loss ratio rebates paid	\$ 8,064,904	-	-	-	\$ 8,064,904
(3) Medical loss ratio rebates unpaid	\$ 1,434,756	-	-	-	\$ 1,434,756
(4) Plus reinsurance assumed amounts	xxxx	XXXX	xxxx	XXXX	XXXX
(5) Less reinsurance ceded amounts	xxxx	XXXX	xxxx	XXXX	xxxx
(6) Rebates unpaid net of reinsurance	xxxx	XXXX	XXXX	XXXX	XXXX

E. Risk Sharing Provisions of the Affordable Care Act

(1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)?

Yes

0

(2) Impact of Risk Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year

for the current Year		ANACHINIT
a. Permanent ACA Risk Adjustment Program		AMOUNT
Assets		
	\$	9,064,000
 Premium adjustments receivable due to ACA Risk Adjustment (including high-risk payments) Liabilities 	Ş	9,064,000
2. Risk adjustment user fees payable for ACA Risk Adjustment		79,294
3. Premium adjustments payable due to ACA Risk Adjustment (including high-risk payments)		4,607,240
Operations (Revenue & Expense)		
4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment		4,456,760
5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)		78,678
b. Transitional ACA Reinsurance Program		
Assets		
1. Amounts recoverable for claims paid due to ACA Reinsurance		0
2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)		0
3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance		0
Liabilities		
4. Liabilities for contributions payable due to ACA Reinsurance – not reported as ceded premium		0
5. Ceded reinsurance premiums payable due to ACA Reinsurance		0
6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance		0
Operations (Revenue & Expense)		
7. Ceded reinsurance premiums due to ACA Reinsurance		0
8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected		
payments		0
9. ACA Reinsurance contributions – not reported as ceded premium		0
c. Temporary ACA Risk Corridors Program		
Assets		
1. Accrued retrospective premium due to ACA Risk Corridors		0
Liabilities		
2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors		0
Operations (Revenue & Expense)		
3. Effect of ACA Risk Corridors on net premium income (paid/received)		0

4. Effect of ACA Risk Corridors on change in reserves for rate credits

(3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any non-admission) and liability balances along with the reasons for adjustments to prior year balance.

reasons for adjustments to prior year balance.											
	Accrued [During the	Received o	r Paid as of							
	Prior Year	on Business	the Curre	nt Year on						Unsettled Ba	alances as of
	Wri	tten	Busi	ness	Differ	ences	Adjı	ustments		the Repo	rting Date
	Before De	c 31 of the	Written Be	fore Dec 31	Prior Year	Prior Year				Cumulative	Cumulative
	Prior	Year	of the Pi	rior Year	Accrued	Accrued				Balance	Balance
					Less	Less	To Prior			from Prior	from Prior
					Payments	Payments	Year	To Prior Year		Years (Col 1	Years (Col
					(Col 1 - 3)	(Col 2 - 4)	Balances	Balances		- 3 + 7)	2-4+8)
	1	2	3	4	5	6	7	8		9	10
									R		
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	ef	Receivable	(Payable)
a. Permanent ACA Risk											
Adjustment Program											
1. Premium adjustments											
receivable (including high-											
risk payments)	4,700,000	0	.12,099,265	0	.(7,399,265)	0	7,399,265	0	Α	0	0
2. Premium adjustments											
(payable) (including high-											
risk payments)	0	5,900,000	0	1 108 172	0	1 701 828		(1,791,828)	B	0	0
' ' '		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		4,100,172		1,731,626		(1,751,626)	0		
3. Subtotal ACA Permanent											
Risk Adjustment Program	4 700 000	5 900 000	12 000 265	1 100 172	17 200 2651	1 701 929	7 200 265	(1,791,828)		0	0
b. Transitional ACA Reinsurance	4,700,000	3,900,000	.12,099,203	4,108,172	.(7,399,203)	1,791,828	7,399,203	(1,791,626)			
Program											
1. Amounts recoverable for	_	_	_	_	_	_	_	_		_	_
claims paid	0	0	0	0	0	0	0	0	С	0	0
2. Amounts recoverable for											
claims unpaid (contra											
liability)	0	0	0	0	0	0	0	0	D	0	0
3. Amounts receivable relating											
to uninsured plans	0							0	F	0	0
4. Liabilities for contributions									-		
payable due to ACA											
Reinsurance - not reported									L		0
as ceded premium	0	0	0	0	0	0	0	0	F	0	0
5. Ceded reinsurance											
premiums payable	0	0	0	0	0	0	0	0	G	0	0
6. Liability for amounts held											
under uninsured plans	0	0	0	0	0	0	0	0	Н	0	0
7. Subtotal ACA Transitional											
Reinsurance Program	0	0	n	0			0	0		0	0
c. Temporary ACA Risk Corridors											
Program											
_											
1. Accrued retrospective	_	_	_	_	_	_	_	_		_	_
premium	0	0	0	0	0	0	0	0		0	0
2. Reserve for rate credits or											
policy experience rating											
refunds	0	0	0	0	0	0	0	0	J	0	0
3. Subtotal ACA Risk Corridors											
Program	0	0	0	0	0	0	0	0		0	0
d. Total for ACA Risk Sharing											
Provisions											
	4,700,000	5,900,000	.12,099,265	4,108,172	.(7,399,265)	1,791,828	7,399,265	(1,791,828)		0	0
L	, ,	.,,	, , _ 30	,,-:=	, , , 0)	,,	, , _ 30	. ,,)			

Explanation of Adjustments

- A Adjustment was made to reflect the ending balance as reported in the Centers for Medicare & Medicaid Services "Summary Report on Transitional Reinsurance Payments and Permanent Risk Adjustment Transfers for the 2021 Benefit Year"
- Adjustment was made to reflect the ending balance as reported in the Centers for Medicare & Medicaid Services "Summary Report on Transitional Reinsurance Payments and Permanent Risk Adjustment Transfers for the 2021 Benefit Year"
- C Not Applicable
- D Not applicable
- E Not applicable
- F Not applicable
- G Not applicable
- H Not applicable
- I Not applicable
- J Not applicable

(4) Roll forward of Risk Corridors Asset and Liability Balances by Program Benefit Year.

Risk Corridors Program Year	Accrued During the Prior Year on Business Written Before Dec 31 of the Prior Year		Business Written Before Dec 31 of the Prior Year		Differences Prior Year		Year Year Balances Balances		Unsettled Balances as of the Reporting Date Cumulative Balance from Frior Years (Col 1 - 3 + 7) - 4 + 8)		
	1 Receivable	(Payable)	3 Receivable	(Pavable)	5 Receivable	(Pavable)	7 Receivable	8 (Payable)	Ref	9 Receivable	10 (Payable)
a. 2014 1. Accrued retrospective premium	0	0	0	, , ,			0		АВ	0	0
Reserve for rate credits or policy experience rating refunds	0	0	0	0	0	0	0	0			0
Reserve for rate credits or policy experience rating refunds	0	0	0 0	0	0	0	0 0	0 0	F	0	0

Explanation of Adjustments

- A Not applicable
- B Not applicable
- C Not applicable
- D Not applicable
- E Not applicable
- F Not applicable

24(4)d (Columns 1 through 10) should equal 24E(3)c3 (Column 1 through 10 respectively)

(5) ACA Risk Corridors Receivable as of Reporting Date

	1	2	3	4	5	6
	Estimated					
	Amount to be	Non-Accrued		Asset Balance		
	Filed or Final	Amounts for		(Gross of Non-		Net Admitted
Risk Corridors	Amount Filed with	Impairment or	Amounts received	admissions)		Asset
Program Year	CMS	Other Reasons	from CMS	(1-2-3)	Non-admitted	(4-5)
a. 2014	0	0	0	0	0	0
b. 2015	0	0	0	0	0	0
c. 2016	0	0	0	0	0	0
e. Total (a+b+c)	0	0	0	0	0	0

24E(5)d (Columns 4) should equal 24E(3)c1 (Column 9) 24E(5)d (Columns 6) should equal 24E(2)c1

25. Change in Incurred Claims and Claim Adjustment Expenses

A. Reserves as of December 31, 2022 were \$16,885,067. As of December 31, 2022, \$11,970,884 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$66,744 as a result of re-estimation of unpaid claims and claim adjustments expenses principally on the comprehensive line of business. Therefore, there has been a \$131,004 favorable prior year development since December 31, 2021 to December 31, 2022. The increase is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.

NOTES TO FINANCIAL STATEMENTS

B. There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid claims and claim adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2022 and 2021.

27. Structured Settlements

Not applicable at December 31, 2022 and 2021.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

	ı			1	
	Estimated Pharmacy	Pharmacy		Actual Rebates	Actual Rebates
	Rebates as Reported on	Rebates as Billed or	Actual Rebates Received	Received Within 91 to	Received More Than
Quarter	Financial Statements	Otherwise	Within 90 Days	180 Days of	180 Days After
Quarter	Statements	Confirmed	of Billing	Billing	Billing
12/31/2022	\$ 2,598,343	\$ 2,299,493	\$ -	\$ -	\$ -
09/30/2022	\$ 2,806,214	\$ 2,186,566	\$ -	\$ -	\$ -
06/30/2022	\$ 2,226,994	\$ 2,080,775	\$ -	\$ 2,365,187	\$ -
03/31/2022	\$ 1,880,181	\$ 1,864,762	\$ -	\$ 2,075,015	\$ (68,571)
12/31/2021	\$ 2,030,821	\$ 1,555,514	\$ 101,445	\$ 2,021,625	\$ 8,706
09/30/2021	\$ 1,360,561	\$ 1,538,880	\$ -	\$ 1,799,751	\$ (142,513)
06/30/2021	\$ 2,393,120	\$ 1,555,127	\$ -	\$ 1,676,246	\$ (122,854)
03/31/2021	\$ 1,466,328	\$ 1,360,651	\$ -	\$ 1,504,389	\$ (91,215)
12/31/2020	\$ 1,979,071	\$ 1,271,773	\$ -	\$ 1,877,069	\$ (22,837)
09/30/2020	\$ 1,030,659	\$ 1,340,135	\$ -	\$ 1,791,216	\$ 81,242
06/30/2020	\$ 2,510,777	\$ 1,519,333	\$ -	\$ 1,615,029	\$ 53,510
03/31/2020	\$ 2,235,403	\$ 1,536,263	\$ -	\$ 1,521,155	\$ 54,651

B. Risk Sharing Receivables

Not applicable at December 31, 2022 and 2021.

29. Participating Policies

Not applicable at December 31, 2022 and 2021.

30. Premium Deficiency Reserves

The Company recorded a liability for premium deficiency reserves at December 31, 2022.

1. Liability carried for premium deficiency reserves \$ 15,800,000 2. Date of the most recent evaluation of this liability 12/31/2022 Yes X No

3. Was anticipated investment income utilized in the calculation?

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation recoveries in its determination of the liability for unpaid claims and reduced such liability by \$0 for the years ended December 31, 2022 and 2021.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?		Yes [X] No []
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.				
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	s [X]	No [] N/A []
1.3	State Regulating?		Main	е	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [] No [X]
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group.				
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?		Yes [] No [X]
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made		12/31/2	2021	
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released		12/31/2	2017	
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).		10/04/2	2019	
3.4	By what department or departments? Maine Bureau of Insurance				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	s []	No [] N/A [Х]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	s []	No [] N/A [Х]
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or cont a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?		Yes [] No [X]
4.2	4.12 renewals?		Yes [] No [X]
	premiums) of: 4.21 sales of new business?		-] No [X] No [X	-
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [] No [X]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.				
	1 2 3 Name of Entity NAIC Company Code State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended revoked by any governmental entity during the reporting period?		Yes [] No [X]
6.2	If yes, give full information:				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control;				%
	1 2 Nationality Type of Entity	7			

	Have any provisions of the code of ethics been waived for any of the sp. If the response to 14.3 is yes, provide the nature of any waiver(s).	pecified officers?				Yes []	No [)	[]
	If the response to 14.2 is yes, provide information related to amendmen	nt(s).				Yes [J	No [)	(]
	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain: Has the code of ethics for senior managers been amended?					Voc. I	1	No t v	y 1
	 a. Honest and ethical conduct, including the ethical handling of actual or relationships; b. Full, fair, accurate, timely and understandable disclosure in the period. Compliance with applicable governmental laws, rules and regulations. d. The prompt internal reporting of violations to an appropriate person of the period. 	or apparent conflicts of interest between personal bdic reports required to be filed by the reporting en s;	and prof			-	-	-	,
13.4 14.1	Are the senior officers (principal executive officer, principal financial offi similar functions) of the reporting entity subject to a code of ethics, which	ficer, principal accounting officer or controller, or p	ersons p	erformin	g] No [Yes [)]]
	Have there been any changes made to any of the trust indentures during If answer to (13.3) is yes, has the domiciliary or entry state approved the					Yes [J	No [. J
	Does this statement contain all business transacted for the reporting er					Yes []	No []
13. 13.1	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES What changes have been made during the year in the United States m.	nanager or the United States trustees of the report							
12.2	If, yes provide explanation:								
	•	usted carrying value							
		cels involved							
		estate holding company				100 [1	110 [/	, 1
11. 12.1	What is the name, address and affiliation (officer/employee of the reportirm) of the individual providing the statement of actuarial opinion/certific Kathleen Ely FSA, MAAA, Millman 80 Lamberton Road Windsor, CT Does the reporting entity own any securities of a real estate holding cor	ication? 06095 Actuary/Consultant				l saV	1	No ()	(1
10.6	Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain] No []	N/A	[
									_
10.3 10.4	Has the insurer been granted any exemptions related to the other requiallowed for in Section 18A of the Model Regulation, or substantially sim If the response to 10.3 is yes, provide information related to this exemp	irements of the Annual Financial Reporting Model nilar state law or regulation?	Regulat	ion as		Yes []	No [)	(]
10.2	law or regulation? If the response to 10.1 is yes, provide information related to this exemp					Yes []	No [)	(]
10.1	Has the insurer been granted any exemptions to the prohibited non-auc requirements as allowed in Section 7H of the Annual Financial Reporting	dit services provided by the certified independent ng Model Regulation (Model Audit Rule), or subst	public ac antially s	countan	t ite				
9.	What is the name and address of the independent certified public acco KPMG LLC One Financial Plaza 755 Main Street Hartford, CT 06103	<u> </u>							
8.6	Federal Reserve System or a subsidiary of the depository institution ho If response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?	of a company that has otherwise been made subj	ect to the	е		Yes [] No [No [)	_
8.5	Is the reporting entity a depository institution holding company with sign					Voo [,	No F \	v 1
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC	_		
	1	2	3	4	5	6	1		
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities firms?					Yes []	No [)	[]
8.1 8.2	Is the company a subsidiary of a depository institution holding company If the response to 8.1 is yes, please identify the name of the DIHC.	y (DINC) of a DINC fisell, regulated by the Federa				Yes [J	No [)	.]

	o 15.1 is yes, indicate the American Bankers Association (AB er of Credit and describe the circumstances in which the Lette				
1 American Bankers Association (ABA) Routing	2		3	4	
Number	Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit	Amo	
	BOARD O	F DIRECTOR	S		
thereof?	or sale of all investments of the reporting entity passed upon			Yes [X]	No
thereof?	ng entity keep a complete permanent record of the proceedin	·····		Yes [X]	No
part of any of its	g entity an established procedure for disclosure to its board o officers, directors, trustees or responsible employees that is i	in conflict or is likely	to conflict with the official duties of such	Yes [X]	No
•	EIN	ANCIAL			
Has this stateme	ent been prepared using a basis of accounting other than Stat siples)?	tutory Accounting Pr	inciples (e.g., Generally Accepted	Yes [No
	ned during the year (inclusive of Separate Accounts, exclusiv				
			20.12 To stockholders not officers	.\$	
			20.13 Trustees, supreme or grand (Fraternal Only)	•	
Total amount of	loans outstanding at the end of year (inclusive of Separate A	ccounts exclusive of		\$	
policy loans):	ioans outstanding at the end of year (inclusive of Separate A	ccounts, exclusive of	20.21 To directors or other officers	.\$	
. , ,			20.22 To stockholders not officers		
			20.23 Trustees, supreme or grand		
Mara any assata	reported in this statement subject to a contractual obligation	to transfer to another	(Fraternal Only)	\$	
obligation being	reported in this statement subject to a contractual obligation reported in the statement?	i to transier to anothe	er party without the hability for such	Yes [No
	amount thereof at December 31 of the current year:		21.21 Rented from others		
			21.22 Borrowed from others	\$	
			21.23 Leased from others		
			21.24 Other	.\$	
Does this statem	ent include payments for assessments as described in the A	nnual Statement Ins	tructions other than guaranty fund or	v .	
	ation assessments?				
If answer is yes:			2.21 Amount paid as losses or risk adjustment		
			2.22 Amount paid as expenses		
Does the reportir	ng entity report any amounts due from parent, subsidiaries or				
	ny amounts receivable from parent included in the Page 2 am	_			
Does the insurer	utilize third parties to pay agent commissions in which the ar	mounts advanced by	the third parties are not settled in full within	Yes [
	o 24.1 is yes, identify the third-party that pays the agents and				
		Is the			
		Third-Party Age			
	Name of Third-Party	a Related Part (Yes/No)	ny		
		` ′			
		STMENT			

25.02	If no, give full and complete information relating thereto					
25.03	For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)					
25.04	For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions.	\$				
25.05	For the reporting entity's securities lending program, report amount of collateral for other programs.	\$				
25.06	Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract?] No [] N/A [X]				
25.07	Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%?] No [] N/A [X]				
25.08	8 Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending?					
25.09	For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:					
	25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. 25.092 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. 25.093 Total payable for securities lending reported on the liability page.	\$0				
26.1	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03).	Yes [X] No []				
26.2	If yes, state the amount thereof at December 31 of the current year: 26.21 Subject to repurchase agreements 26.22 Subject to dollar repurchase agreements 26.24 Subject to dollar repurchase agreements 26.25 Placed under option agreements 26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies 26.30 Pledged as collateral - excluding collateral pledged to an FHLB 26.31 Pledged as collateral to FHLB - including assets backing funding agreements 26.32 Other	\$.				
26.3	For category (26.26) provide the following:					
	1 2 Nature of Restriction Description	3 Amount				
27.1	Does the reporting entity have any hedging transactions reported on Schedule DB?	_				
27.2	If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?] No [] N/A [
INES 2	If no, attach a description with this statement. 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:					
27.3	Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity?.	Yes [] No []				
27.4	If the response to 27.3 is YES, does the reporting entity utilize:					
	27.41 Special accounting provision of SSAP No. 108	Yes [] No []				
27.5	By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following:	Yes [] No []				
	 following: The reporting entity has obtained explicit approval from the domiciliary state. Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21. Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount. Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual days to desirable intention of the company in the comp					
28.1	Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.	Yes [] No [X]				
	Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the					
	Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity?	\$				
28.2 29.	Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? If yes, state the amount thereof at December 31 of the current year. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook? For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:	\$				
28.2 29.	Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity?	\$				
28.2 29.	Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? If yes, state the amount thereof at December 31 of the current year. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook, complete the following:	\$				

GENERAL INTERROGATORIES

9.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

		1 Name(s)	2 Location(s) Comple		3 Complete Explanatio	n(s)				
29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?							[]	 No [X]	
		1 ustodian	2 New Custodian	3 Date of Cha		4 Reason				
	make investment deci	ent – Identify all investment advisions on behalf of the reporting occess to the investment accounts	entity. For assets that are manag							
	Key Private Bank	1 Name of Firm or Individual	Affil	2 iation						
		ns/individuals listed in the table for ith a "U") manage more than 10°					Yes	[X]	No []
		viduals unaffiliated with the repo under management aggregate to					Yes	[X]	No []
	For those firms or indithe table below.	ividuals listed in the table for 29.0	05 with an affiliation code of "A"	(affiliated) or "U" (unaff	iliated), p	provide the information for				
	1		2	3		4		Inve: Mana	5 stment gement	ì
	Central Registration Depository Number	Name of Firm	m or Individual	Legal Entity Identific		Registered With			ement) Filed	
	Not Applicable	Key Private Bank		HUX2X73FUCYHUVH1BK78		Office of the Comptroller the Currency		DS		
20.4		***.	and an article in Cabadala D. D.	-t 0 /diifd	: 4- 4-	0		ļ		_
	Exchange Commission	tity have any diversified mutual fund (SEC) in the Investment Comp					Yes	[]	No [X]
30.2	If yes, complete the fo	llowing schedule:								

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

 $30.3\,\,$ For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation
_			

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	123,429,471	110,235,375	(13, 194, 096)
31.2 Preferred stocks	0		0
31.3 Totals	123,429,471	110,235,375	(13, 194, 096)

31.4 Describe the sources or methods utilized in determining the fair values: IDC Fixed Income							
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes	s [)	(]	No I	[]	l
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes	s [)	(]	No I	[]	J
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:						
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes	s [)	(]	No	[]	
33.Z	ii no, iist exceptions.						
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments.						
	c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.						
	Has the reporting entity self-designated 5GI securities?	Yes	s [1	No I	[X]	
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.						
	c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.						
	Has the reporting entity self-designated PLGI securities?	Yes	s []	No I	[X]	ı
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019.						
	b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.						
	c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.						
	 d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. 						
	f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.						
	Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yes	s []	No	[X]	ı
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.						
	b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.						
	 d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. 						
	Has the reporting entity colled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [1 1	No [X 1	N/	AΓ	

38.1	Does the reporting entity directly hold cryptocurrencies?			. Yes []	No [Х]
38.2	If the response to 38.1 is yes, on what schedule are they reported?						
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums	s on policies?		. Yes []	No [Х]
39.2	If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately conv. 39.21 Held directly			· Yes []	No []
	39.22 Immediately converted to U.	S. dollars		. Yes []	No []
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premium	ns or that are held directly					
	Name of Cryptocurrency Dire	2 Immediately onverted to USD, ectly Held, or Both	3 Accepted for Payment of Premiums				
				<u></u>			
40.1 40.2	Amount of payments to trade associations, service organizations and statistical or rating bureaus. List the name of the organization and the amount paid if any such payment represented 25% or					19	57,446
40.2	service organizations and statistical or rating bureaus during the period covered by this statemen	nt.		115,			
	Name	2 Amour	t Paid				
	Health Plan Alliance LLC Maine Association of Health Plans		44 , 533				
41.1	Amount of payments for legal expenses, if any?			\$		10	08,012
41.2	List the name of the firm and the amount paid if any such payment represented 25% or more of during the period covered by this statement.	the total payments for leg	al expenses				
	1 Name	2 Amour					
	Kozak & Gayer, PA		107,374				
42.1	Amount of payments for expenditures in connection with matters before legislative bodies, office	ers or departments of gove	ernment, if any?	\$		(50,250
42.2	List the name of the firm and the amount paid if any such payment represented 25% or more of connection with matters before legislative bodies, officers, or departments of government during						
	1	. 2					
	Name Government Strategies	Amour					
	determinent etrategree		55,250				

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in fo						
1.2							
1.3							
	1.31 Reason for excluding						
			•				
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Aliei Indicate total incurred claims on all Medicare Supplement Insurance						
1.5	Indicate total incurred claims on all Medicare Supplement Insurance	Most current three years:	»				
1.6	ilidividual policies.	1.61 Total premium earned	e		0		
		1.62 Total incurred claims	Φ		٥		
		1.63 Number of covered lives					
		All years prior to most current three years:			0		
		1.64 Total premium earned			0		
		1.65 Total incurred claims	D		٥		
		1.66 Number of covered lives					
		1.66 Number of covered lives			0		
4 7	Occurs malicines	Mark assessed there are an					
1.7	Group policies:	Most current three years:	•		0		
		1.71 Total premium earned					
		1.72 Total incurred claims					
		1.73 Number of covered lives			0		
		All years prior to most current three years:					
		1.74 Total premium earned	\$		0		
		1.75 Total incurred claims					
		1.76 Number of covered lives			0		
•	1110. T1						
2.	Health Test:	4					
		1 2 Current Year Prior Year					
	2.1 Premium Numerator						
	2.2 Premium Denominator						
	2.3 Premium Ratio (2.1/2.2)						
	2.4 Reserve Numerator						
	2.5 Reserve Denominator						
	2.6 Reserve Ratio (2.4/2.5)						
	2.0 Neselve Natio (2.4/2.0)	1.000					
3.2	returned when, as and if the earnings of the reporting entity permits? If yes, give particulars:		100 [, 110 [~ 1		
4.1	Have copies of all agreements stating the period and nature of hospitals', phys dependents been filed with the appropriate regulatory agency?		Yes [X] No [[]		
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	ese agreements include additional benefits offered?	Yes [] No [. 1		
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [] No [. 1		
5.2	If no, explain:						
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	-				
		5.32 Medical Only					
		5.33 Medicare Supplement					
		5.34 Dental & Vision					
		5.35 Other Limited Benefit Plan					
		5.36 Other	.\$				
6.	Describe arrangement which the reporting entity may have to protect subscribe hold harmless provisions, conversion privileges with other carriers, agreements agreements:						
7.1	Does the reporting entity set up its claim liability for provider services on a serv	rice date basis?	Yes [X] No []		
7.2	If no, give details						
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year . 8.2 Number of providers at end of reporting year					
9.1	Does the reporting entity have business subject to premium rate guarantees? .		Yes [] No [[X]		
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months. 9.22 Business with rate guarantees over 36 months					

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?						Yes [X]	No []
10.2	If yes:	1 1	0.21 Maximum am 0.22 Amount actua 0.23 Maximum am 0.24 Amount actua	\$	531,771			
11.1	Is the reporting entity organized as:			11.13 An Indivi	al Group/Staff Mod dual Practice Asso Model (combinatio	ciation (IPA), or,	Yes []	No [X] No [X] No [X]
11.2 11.3	If yes, show the name of the state requiring such minimum capital and surplus.							No [] Maine 18,171,160
11.4 11.5 11.6	If yes, show the amount required Is this amount included as part of a contingency reserve in stockholder's equity? If the amount is calculated, show the calculation 200% of Health Risk-Based Capital Authorized Control Level (200% of \$9,085,580)							No [X]
12.	List service areas in which reporting entity is license	ed to operate:						
	New Hamp	shire		e Area				
13.1	Do you act as a custodian for health savings account	nts?					Yes []	No [X]
13.2	3.2 If yes, please provide the amount of custodial funds held as of the reporting date\$							
13.3	.3 Do you act as an administrator for health savings accounts?						Yes []	No [X]
13.4 14.1 14.2	If yes, please provide the balance of funds administ Are any of the captive affiliates reported on Schedul If the answer to 14.1 is yes, please provide the follow	e S, Part 3, auth] N/A [X]
	1	2	3	4		Supporting Reserv		
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other	
15.	Provide the following for individual ordinary life insuceded):	rance* policies (l	J.S. business only	, 15.1 [15.2]		itten	\$	
	*Ordinary Life Insurance Includes							
	Term(whether full un Whole Life (whether Variable Life (with or Universal Life (with o Variable Universal Li	full underwriting, without seconda r without second	limited underwritir ry gurarantee) ary gurarantee)	ng, jet issue, "short				
16.	Is the reporting entity licensed or chartered, register	ed, qualified, elig	jible or writing bus	iness in at least tw	o states?		Yes [X] No	, []
16.1	If no, does the reporting entity assume reinsurance domicile of the reporting entity?						Yes [] No)[]

FIVE-YEAR HISTORICAL DATA

		1 2022	2 2021	3 2020	4 2019	5 2018
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	165,982,001	184,016,793	218,975,407	182,400,876	170,659,367
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement	18, 171, 160	14,451,650	14,465,520	15,932,156	27,545,738
4.	Total capital and surplus (Page 3, Line 33)					
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	205,096,908	164,254,590	243,934,497	242,544,604	380,316,002
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	(20,648,045)	(43,566,626)	42,999,018	799,044	99,596,671
	Risk-Based Capital Analysis	. , , ,			,	, ,
14.	Total adjusted capital	118,783,016	120,389,917	140 , 140 , 003	84,188,921	57,333,556
15.	Authorized control level risk-based capital					
	Enrollment (Exhibit 1)	, ,	, ,		, ,	
16.	Total members at end of period (Column 5, Line 7)	29,300	22,984	26,130	37,062	50,052
17.	Total members months (Column 6, Line 7)					
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0		,		, .	
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)					
20.	Cost containment expenses	4.1	4.5	4.0	4.5	2.7
21.	Other claims adjustment expenses	2.5	2.4	1.8	2.6	2.1
22.	Total underwriting deductions (Line 23)	102.1	114.2	77.3	90.5	93.7
23.	Total underwriting gain (loss) (Line 24)	(2.1)	(14.1)	22.8	9.6	6.6
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	11,095,324	17,259,760	20,259,444	32,590,939	26,246,949
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	11,226,938	19,459,101	23,237,320	45,498,040	29,226,654
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0		0		
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)		0		0	0
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure				
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?]
If no, please explain:				

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS


Allocated by States and Territories

	Allocated by States and Territories							1				
			1	2	3	4	<u>Di</u>	rect Business O 6 Federal Employees Health	7 Life and Annuity	8	9	10
	States, etc.		Active Status (a)	Accident and Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Benefits Program Premiums	Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
1.	Alabama		N								0	
2.		AK	N								0	
3.	Arizona	AZ	N								0	
4.	Arkansas		N								0	
5. 6.		CA CO	N								0	
7.	Connecticut	CT	N								0	
8.	Delaware	DE	N								0	
9.		DC	N								0	
		-	N								0	
11.	Georgia		N								0	
	Hawaii		N								0	
	Idaho	ID	N								0	
		IL	N								0	
	Indiana	IN	N								0	
16.	lowa	IA	N								0	
17.	Kansas	KS	N								0	
18.	Kentucky	KY	N								0	
	Louisiana		N								0	
20.	Maine	ME	L	206, 176, 600							206, 176,600	
21.	Maryland	MD	N								0	
22.	Massachusetts	MA	N								0	
	=	MI	N								0	
	Minnesota		N								0	
	Mississippi	MS	N								0	
26.		-	N								0	
		MT	N								0	
		NE	N								0	
	Nevada		N								0	
	•		L								0	
31.	New Jersey		N								0	
	New Mexico		N								0	
			N								0	
	North Dakota		N								0	·····
	North Dakota	ND	N								0	
36. 37.			N N								0	
37. 38.	Oregon		N		·····						0	
	Pennsylvania	OR PA	N								0	·····
40.	Rhode Island	PA RI	N							•	n	
41.	South Carolina		N							•••••	0	
42.	South Dakota	SD	N								0	
43.		TN	N							•••••	0	
44.	Texas		N								0	
		UT	N								0	
	Vermont	-	N								0	
			N								0	
	•		N								0	
	West Virginia		N								0	
			N								0	
51.	Wyoming	WY	N								0	
	American Samoa		N								0	
53.	Guam	GU	N								0	
	Puerto Rico		N								0	
	U.S. Virgin Islands	VI	N								0	
56.	Northern Mariana	ME	A.I								_	
E7	Islands	MP	N								0	·····
57. 58		CAN	N								0	
58.	Aggregate Other Aliens	ОТ	XXX	0	0	0	0	0	0	0	0	0
59.	Subtotal		XXX	206, 176, 600	0	0	0	0	0	0	206, 176, 600	0
60.	Reporting Entity Contributions for En Benefit Plans	nployee									0	
61.	Totals (Direct Busine	ess)	XXX	206, 176, 600	0	0	0	0	0	0	206, 176, 600	0
	DETAILS OF WRITE											
58001.			XXX									
58002.			XXX									
58003.			XXX									
58998.	Summary of remainir write-ins for Line 58 f overflow page	from	XXX	0	0	0	0	0	0	0	0	0
58999.	Totals (Lines 58001 t 58003 plus 58998)(Liabove)	through		0	0	0	0	0	0	0	0	0
	Status Counts:								·	· · · · ·		

(a)	Active	Status	Counts:

^{3.} E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0
(b) Explanation of basis of allocation by states, premiums by state, etc.

Allocation is based on the residency of the member or group



NONE